Who Supplies Paracetamol to India from CHINA

To import finished pharmaceutical formulations containing Paracetamol into India, foreign manufacturers must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered, requiring submission of Form CT-20/40/41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process includes providing stability data compliant with ICH Zone IV guidelines and ensuring formulations meet the standards of the Indian Pharmacopoeia. The timeline for import drug registration varies but typically spans several months, depending on the completeness of the application and regulatory review. Paracetamol formulations under HS Code 30049069 are subject to these requirements to ensure safety, efficacy, and quality compliance.

Imported Paracetamol formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data demonstrating the product's shelf-life under ICH Zone IV conditions is also mandatory. Upon arrival, customs drug inspectors perform port inspections to verify documentation and sample products for testing. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.

Between 2024 and 2026, the CDSCO has implemented regulatory updates to streamline the import process for finished pharmaceutical formulations, including Paracetamol. The Production Linked Incentive (PLI) scheme has been extended to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements with China have been established to facilitate smoother trade, including mutual recognition of Good Manufacturing Practices (GMP), which may influence the import dynamics of Paracetamol formulations.

India imports finished Paracetamol formulations to meet domestic demand for various dosage forms not produced locally, such as specialized combinations or packaging. The market size for Paracetamol formulations in India is substantial, with a total export market of $357.3 million across 870 exporters to 170 countries. This indicates a robust demand for Paracetamol formulations, both domestically and internationally.

The Basic Customs Duty (BCD) for Paracetamol formulations under HS Code 30049069 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, along with a Social Welfare Surcharge (SWS) of 10% on the BCD. This results in a total landed duty of approximately 23.536%. There are no specific exemptions or preferential duty rates for imports from China under this HS code.

China is a significant source for India's import of Paracetamol formulations due to its competitive pricing, established manufacturing capabilities, and adherence to international quality standards. While other countries like Germany and the United States also supply Paracetamol formulations, China's market share remains substantial, offering a competitive advantage in terms of cost and supply chain reliability.

India imports Paracetamol formulations from China to access cost-effective products, specialized dosage forms, and formulations not readily available domestically. China's established manufacturing infrastructure and adherence to international quality standards make it a reliable source for these formulations.

Compared to other origins like the European Union and the United States, China offers Paracetamol formulations at more competitive prices. While the EU and US may provide higher-quality products, China's unique advantage lies in its ability to supply large volumes at lower costs, making it an attractive option for Indian importers.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential quality issues. To mitigate these risks, diversifying suppliers, maintaining buffer stocks, and establishing robust quality assurance processes are recommended.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary certifications are in place.

1. 1Obtain a valid Importer Exporter Code (IEC) from DGFT.
2. 2Register the product with CDSCO by submitting Form CT-20/40/41.
3. 3Secure a Drug Import License from DGFT.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
5. 5Ensure compliance with all customs documentation requirements, including advance ruling for HS Code 30049069.

1. 1Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practices (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data demonstrating shelf-life under ICH Zone IV conditions.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors perform port inspections to verify documentation and sample products for testing. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards